The impact of COVID-19 lockdowns on the body mass index of people living with obesity: A UK retrospective cohort study using the UK Clinical Practice Research Datalink.

BACKGROUND: Restrictions implemented by governments during the coronavirus disease 2019 (COVID-19) pandemic affected people's eating habits and physical activity. We investigated the effect of COVID-19 lockdowns and restrictions on body mass index (BMI) and weight in a UK population, according to BMI class, sex, age and ethnicity. METHODS: This retrospective observational cohort study used the Clinical Practice Research Datalink AURUM database. Baseline spanned from 22 March 2017-22 March 2020, and the follow-up lockdown period was from 23 March 2020 (start of the lockdown in the UK) to 13 March 2021. The descriptive analysis included individuals with ≥ 1 valid BMI/weight measurements during both the baseline and follow-up periods, while the model-based analysis comprised individuals with ≥ 1 valid measurement(s) during baseline. Results were stratified by baseline BMI category, sex, age and ethnicity. RESULTS: In the descriptive analysis (n = 273,529), most individuals did not change BMI category post-lockdown (66.4-83.3%). A greater proportion of women (12.6%) than men (9.5%) moved up BMI categories post-lockdown. Compared with older groups, a higher proportion of individuals < 45 years old increased post-lockdown BMI category. The model-based analysis (n = 938,150) revealed consistent trends, where changes in body weight and BMI trajectories pre- and post-lockdown were observed for women and for individuals < 45 years. CONCLUSION: During COVID-19 restrictions, women and young individuals were more likely than other groups to increase BMI category and weight post-lockdown.

The views of teenagers with obesity, their caregivers, and doctors: a plain language summary of the ACTION Teens global survey.

WHAT IS THIS SUMMARY ABOUT?: This is a summary of a research survey called ACTION Teens. In our survey, 12,987 people from 10 countries answered questions about obesity. They were: 5275 teenagers with obesity, 5389 caregivers of teenagers with obesity, and 2323 doctors who provide medical care for teenagers with obesity. WHAT WERE THE MAIN RESULTS OF THE SURVEY?: Most teenagers with obesity were worried about their weight and thought that losing weight was their responsibility. Many teenagers had already tried to lose weight. For teenagers, wanting to be more fit or in better shape was the top reason for wanting to lose weight. Some caregivers did not realize how worried their teenager was about their own weight. There were also some caregivers who were not aware of their teenager's recent attempts to lose weight. As a group, the doctors did not know the main reasons why teenagers want to lose weight. They also did not know the main reasons preventing teenagers from losing weight. WHAT DO THE RESULTS OF THE SURVEY MEAN?: Teenagers with obesity will be better supported and understood if there is better communication between teenagers, caregivers, and doctors. Clinical Trial Registration: NCT05013359 (ClinicalTrials.gov).

Misalignment among adolescents living with obesity, caregivers, and healthcare professionals: ACTION Teens global survey study.

BACKGROUND: There is limited evidence regarding the experiences, challenges, and needs of adolescents living with obesity (ALwO), their caregivers, and healthcare professionals (HCPs). OBJECTIVES: The cross-sectional, survey-based global ACTION Teens study aimed to identify perceptions, attitudes, behaviours, and barriers to effective obesity care among ALwO, caregivers of ALwO, and HCPs. METHODS: ALwO (aged 12 to <18 years; N = 5275), caregivers (N = 5389), and HCPs treating ALwO (N = 2323) from 10 countries completed an online survey (August-December 2021). RESULTS: Most ALwO perceived their weight as above normal (76% vs. 66% of caregivers), were worried about its impact on their health (85% vs. 80% of caregivers), and recently made a weight loss attempt (58%). While 45% of caregivers believed ALwO would slim down with age, only 24% of HCPs agreed. Most commonly reported weight loss motivators for ALwO were wanting to be more fit/in better shape according to ALwO (40%) and caregivers (32%), and improved confidence/social life according to HCPs (69%). ALwO weight loss barriers included lack of hunger control (most commonly reported by ALwO/caregivers), lack of motivation, unhealthy eating habits (most commonly agreed by HCPs), and lack of exercise. CONCLUSIONS: Misalignment between ALwO, caregivers, and HCPs-including caregivers' underestimation of the impact of obesity on ALwO and HCPs' misperception of key motivators/barriers for weight loss-suggests a need for improved communication and education.

Patient motivation to lose weight: Importance of healthcare professional support, goals and self-efficacy.

BACKGROUND: People with obesity (PwO) often struggle to achieve and maintain weight loss. This can perpetuate and/or be influenced by feelings of low motivation. This analysis from ACTION-IO data identified factors associated with PwO motivation to lose weight. METHODS: PwO completed an online survey in 11 countries. Exploratory multinomial logistic regression analyses identified independent variables associated with self-report of feeling motivated versus not motivated to lose weight. RESULTS: Data from 10,854 PwO were included (5,369 motivated; 3,312 neutral; 2,173 not motivated). Variables associated with feeling motivated versus not motivated included (odds ratio [95% confidence interval]): acknowledgement of healthcare professional (HCP) responsibility to contribute to weight loss (2.32 [1.86-2.88]), comfort in talking to their HCP about weight (1.46 [1.24-1.72), agreement that it is easy to lose weight (1.73 [1.30-2.31]), and a goal of reducing risks from excess weight (1.45 [1.22-1.73]). Conversely, if PwO considered obesity less important than other diseases they were less likely to report feeling motivated (0.49 [0.41-0.58]). PwO who reported being motivated to lose weight were more likely to exercise ≥5 times a week versus <1 time a week (2.77 [2.09-3.68]) than those who reported they were not motivated. CONCLUSIONS: Positive interactions with HCPs, self-efficacy, setting goals and knowledge of the importance of weight management, in addition to regular exercising, may increase PwO motivation for weight loss. Appropriate HCP support may help PwO who are ready to engage in weight management. CLINICAL TRIAL REGISTRATION: NCT03584191.

The 3Ds - Discussion, diagnosis and direction: Elements for effective obesity care by healthcare professionals.

BACKGROUND: The care of people with obesity is often suboptimal due to both physician and patient perceptions about obesity itself and clinical barriers. Using data from the ACTION-IO study, we aimed to identify factors that might improve the quality of obesity care through adoption of the 3D approach (Discussion, Diagnosis and Direction [follow-up]) by healthcare professionals (HCPs). METHODS: An online survey was completed by HCPs in 11 countries. Exploratory beta regression analyses identified independent variables associated with each component of the 3D approach. RESULTS: Data from 2,331 HCPs were included in the statistical models. HCPs were significantly more likely to initiate weight discussions and inform patients of obesity diagnoses, respectively, if (odds ratio [95% confidence interval]): they recorded an obesity diagnosis in their patient's medical notes (1.59, [1.43-1.76] and 2.16 [1.94-2.40], respectively); and they were comfortable discussing weight with their patients (1.53 [1.39-1.69] and 1.15 [1.04-1.27]). HCPs who reported feeling motivated to help their patients lose weight were also more likely to initiate discussions (1.36 [1.21-1.53]) and schedule follow-up appointments (1.21 [1.06-1.38]). By contrast, HCPs who lacked advanced formal training in obesity management were less likely to inform patients of obesity diagnoses (0.83 [0.74-0.92]) or schedule follow-up appointments (0.69 [0.62-0.78]). CONCLUSION: Specific actions that could improve obesity care through the 3D approach include: encouraging HCPs to record an obesity diagnosis; providing tools to help HCPs feel more comfortable initiating weight discussions; and provision of training in obesity management. CLINICAL TRIAL REGISTRATION: NCT03584191.

Características clínicas de pacientes pediátricos internados por Influenza A: comparación de dos subtipos virales (H1N1) y (H3N2) / Clinical characteristics of pediatric patients hospitalized due to Influenza A: comparison of two viral subtypes (H1N1 and H3N2)

Influenza is a respiratory disease ocasionated by influenza virus A and B. Is a disease with high morbi-mortality world-wide. Influenza produces an acute febrile respiratory illness with cough, headache and myalgias for 3-4 days, with simptoms that may persist for as long as 2 weeks. There are three types of influenza virsuses: A, B and C, of whom the type a has a higher ability to originate pandemias and is subclassified according to their surface antigens: hemaglutinine (H) and neuraminidase (N). Of the capacity of mutation that has the influenza virus and the consequent expression of different proteins, can modify its virulence. The transmission route is through direct contact with secretetory repirations. The transmission route is through direct contact with secretetory repirations. The incubation period is scant, between 12-72 hs. The aim of this study was to compare the clinical characteristics demographicals and evolutive of pediatric patients hospitalized because by Influenze A: subtypes H1N1 (pdm2009) and H3N2. An observative study was performed, retrospective, using data of hospitalizations of children during the years 2016 and 2017 with influenza A confirmed by laboratory. The study also, aimed to evaluate if the viral subtype constitutes a factor of risk, independent for complicated hospitalization (admission to intensive care and/or development of complications) in hospitalized children. The results obtained in the study are detailed in the paper. In conclusion, both viral subtypes affected mainly to children with risk factors. The viral subtype H1N1 was related with higher severety in hospitalized children. is of most importance to perform preventive works, specially in vulnerable groups, offering a good cover of immunizations. The clinical parameters arae commented (AU)

Gaps to bridge: Misalignment between perception, reality and actions in obesity.

AIMS: Despite increased recognition as a chronic disease, obesity remains greatly underdiagnosed and undertreated. We aimed to identify international perceptions, attitudes, behaviours and barriers to effective obesity care in people with obesity (PwO) and healthcare professionals (HCPs). MATERIALS AND METHODS: An online survey was conducted in 11 countries. Participants were adults with obesity and HCPs who were primarily concerned with direct patient care. RESULTS: A total of 14 502 PwO and 2785 HCPs completed the survey. Most PwO (68%) and HCPs (88%) agreed that obesity is a disease. However, 81% of PwO assumed complete responsibility for their own weight loss and only 44% of HCPs agreed that genetics were a barrier. There was a median of three (mean, six) years between the time PwO began struggling with excess weight or obesity and when they first discussed their weight with an HCP. Many PwO were concerned about the impact of excess weight on health (46%) and were motivated to lose weight (48%). Most PwO (68%) would like their HCP to initiate a conversation about weight and only 3% were offended by such a conversation. Among HCPs, belief that patients have little interest in or motivation for weight management may constitute a barrier for weight management conversations. When discussed, HCPs typically recommended lifestyle changes; however, more referrals and follow-up appointments are required. CONCLUSIONS: Our international dataset reveals a need to increase understanding of obesity and improve education concerning its physiological basis and clinical management. Realization that PwO are motivated to lose weight offers an opportunity for HCPs to initiate earlier weight management conversations.

Anticuerpos antitransglutaminasa tisular IgA y contra péptidos de gliadina desaminados IgG como predictores de enfermedad celíaca / IgA anti-tissue transglutaminase antibodies and IgG antibodies against deamidated gliadin peptides as predictors of celiac disease

Objetivo. Comparar el rendimiento de anticuerpos antitransglutaminasa IgA (anti-TG2 IgA), antiendomisio IgA (EMA IgA) y antigliadina desaminada IgA/IgG (AGADGP IgA/IgG) para el diagnóstico de enfermedad celiaca. Métodos. Estudio descriptivo en pacientes con enfermedad celíaca. Se dosaron anticuerpos: AGADGP (IgA/IgG), EMA IgA, anti-TG2 IgA y biopsia intestinal. Sexo: mujeres (61 %). Mediana de edad: 78,4 meses. Resultados. Se incluyeron 136 niños; 108 presentaron AGADGP IgA elevado; 124, AGADGP IgG aumentado; 128, EMA IgA positivo; 130, anti-TG2 IgA aumentado. Cuatro de 6 pacientes con anti-TG2 IgA negativos tenían AGADGP IgG elevado. La combinación de los anticuerpos AGADGP IgG + anti-TG2 IgA tuvo una correlación positiva en 134 pacientes y la combinación AGADGP IgG + EMA fue positiva en 133 niños. Conclusión. Se demostró la buena especificidad y sensibilidad de EMA IgA, anti-TG2 IgA y AGADGP IgG. La combinación AGADGP IgG/anti-TG2 mostró sensibilidad del 98-99 % y especificidad del 100 %. La elección de anti-TG2 y AGADGP IgG da excelentes resultados, con bajo costo y no depende del operador.

Objective. To compare the performance of IgA anti-tissue transglutaminase antibodies (IgA anti-tTG), IgA anti-endomysial antibodies (IgA EMA), and IgA/IgG antibodies against deamidated gliadin peptides (IgA/IgG anti-DGP) for the diagnosis of celiac disease. Methods. Descriptive study in patients with celiac disease. Anti-DGP (IgA/IgG), IgA EMA, IgA anti-tTG antibodies were measured and an intestinal biopsy was done. Sex: female (61 %). Median age: 78.4 months old. Results. A total of 136 children were included; 108 had high IgA anti-DGP titers; 124, increased IgG anti-DGP titers; 128, positive IgA EMA titers; and 130, increased IgA anti-tTG titers. High IgG anti-DGP titers were observed in 4/6 patients with negative IgA anti-tTG antibodies. The combination of IgG anti-DGP + IgA anti-tTG antibodies showed a positive correlation in 134 patients and the IgG anti-DGP + EMA combination was positive in 133 children. Conclusion. IgA EMA, IgA anti-tTG, and IgG anti-DGP antibodies exhibited an adequate specificity and sensitivity. The IgG anti-DGP/anti-tTG combination showed a 98-99 % sensitivity and a 100 % specificity. The anti-tTG and IgG anti-DGP option yields excellent results, with a low cost and independence from the observer.

IgA anti-tissue transglutaminase antibodies and IgG antibodies against deamidated gliadin peptides as predictors of celiac disease. / Anticuerpos antitransglutaminasa tisular IgA y contra péptidos de gliadina desaminados IgG como predictores de enfermedad celíaca.

OBJECTIVE: To compare the performance of IgA anti-tissue transglutaminase antibodies (IgA anti-tTG), IgA anti-endomysial antibodies (IgA EMA), and IgA/IgG antibodies against deamidated gliadin peptides (IgA/IgG anti-DGP) for the diagnosis of celiac disease. METHODS: Descriptive study in patients with celiac disease. Anti-DGP (IgA/IgG), IgA EMA, IgA anti-tTG antibodies were measured and an intestinal biopsy was done. Sex: female (61 %). Median age: 78.4 months old. RESULTS: A total of 136 children were included; 108 had high IgA anti-DGP titers; 124, increased IgG anti-DGP titers; 128, positive IgA EMA titers; and 130, increased IgA anti-tTG titers. High IgG anti-DGP titers were observed in 4/6 patients with negative IgA anti-tTG antibodies. The combination of IgG anti-DGP + IgA anti-tTG antibodies showed a positive correlation in 134 patients and the IgG anti-DGP + EMA combination was positive in 133 children. CONCLUSION: IgA EMA, IgA anti-tTG, and IgG anti-DGP antibodies exhibited an adequate specificity and sensitivity. The IgG anti-DGP/anti-tTG combination showed a 98-99 % sensitivity and a 100 % specificity. The anti-tTG and IgG anti-DGP option yields excellent results, with a low cost and independence from the observer.

Objetivo. Comparar el rendimiento de anticuerpos antitransglutaminasa IgA (anti-TG2 IgA), antiendomisio IgA (EMA IgA) y antigliadina desaminada IgA/IgG (AGADGP IgA/IgG) para el diagnóstico de enfermedad celiaca. Métodos. Estudio descriptivo en pacientes con enfermedad celíaca. Se dosaron anticuerpos: AGADGP (IgA/IgG), EMA IgA, anti-TG2 IgA y biopsia intestinal. Sexo: mujeres (61 %). Mediana de edad: 78,4 meses. Resultados. Se incluyeron 136 niños; 108 presentaron AGADGP IgA elevado; 124, AGADGP IgG aumentado; 128, EMA IgA positivo; 130, anti-TG2 IgA aumentado. Cuatro de 6 pacientes con anti-TG2 IgA negativos tenían AGADGP IgG elevado. La combinación de los anticuerpos AGADGP IgG + anti-TG2 IgA tuvo una correlación positiva en 134 pacientes y la combinación AGADGP IgG + EMA fue positiva en 133 niños. Conclusión. Se demostró la buena especificidad y sensibilidad de EMA IgA, anti-TG2 IgA y AGADGP IgG. La combinación AGADGP IgG/anti-TG2 mostró sensibilidad del 98-99 % y especificidad del 100 %. La elección de anti-TG2 y AGADGP IgG da excelentes resultados, con bajo costo y no depende del operador.

Experience of an eating disorders out-patient program in an internal medicine hospital.

PURPOSE: The aim of this study was to develop a successful low budget out-patient program, in an internal medicine hospital, for patients presenting eating disorders in an emerging nation. METHODS: A total of 144 patients were included in a 6 month intervention centered in medical support, with fortnightly medical consultations, monthly counseling by a nutritionist and by a psychiatrist and three psycho-educational courses. The Three Factor Eating Questionnaire and the Eating Disorders Inventory-2 were performed at the beginning and at the end of the study. RESULTS: After 6 months, more than half of the patients who completed the intervention were on remission. Substantial improvement was observed regarding the scores of both instruments after completion of the program. CONCLUSIONS: The outcome of this study compares favorably to previous published data of more intensive programs. These results were obtained having little infrastructure, a low budget and limited human resources, making this a suitable eating disorders program for emerging nations.

Radioiodine treatment in autoimmune hyperthyroidism: analysis of outcomes in relation to dosage.

BACKGROUND: Controversy exists regarding the optimal dose of radioiodine ((131)I) therapy in autoimmune hyperthyroidism (i.e., Graves' Disease). METHODS: In order to evaluate the efficacy and safety of high dose (131)I therapy in autoimmune hyperthyroidism, a retrospective review of patients who received (131)I therapy for Graves' disease from 1980 to 2000 in the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City was carried out. RESULTS: The study population consisted of 596 autoimmune hyperthyroid patients with a mean age of 35 years. The mean follow-up period was 10.31 +/- 2.37 years. Remission of hyperthyroidism occurred in 81.9%, persistent hyperthyroidism was recorded in 14.4% and recurrence in 3.7%. (131)I doses of 5-9 mCi (185-333 MBq) and > or =20 mCi (> or =740 MBq) were associated with remission rates of 65.5% and 87.7% respectively. Remission occurred earlier and more often with high doses of (131)I. The high-dose group (20-30 mCi [740-1110 MBq]) had the lowest rate of persistence (9.7, 27.5 and 34.3%, for 20-30 [740-1110 MBq], 10-14 [370-518 MBq] and 5-9 [185-333 MBq] mCi, respectively p <0.05) and hypothyroidism occurred earlier in this group (p = 0.05). CONCLUSIONS: Remission of autoimmune hyperthyroidism is more likely with doses of 20-30 mCi (740-1110 MBq).

Tratamiento de las fracturas de pelvis / Treatment of pelvic fractures

En el presente trabajo se aborda el tratamiento de las fracturas-luxaciones de pelvis y se analizan sus tendencias más actuales, se revisan las complicaciones y los resultados funcionales de las principales opciones de tratamiento, fundamentalmente la osteosintesis interna y la fijación externa. Se muestra también un listado de referencais bibliográficas que puede facilitar la búsqueda o ampliación de los conocimientos de los profesionales interesados en este tema(AU)

Tratamiento de las fracturas de pelvis / Treatment of pelvic fractures

En el presente trabajo se aborda el tratamiento de las fracturas-luxaciones de pelvis y se analizan sus tendencias más actuales, se revisan las complicaciones y los resultados funcionales de las principales opciones de tratamiento, fundamentalmente la osteosintesis interna y la fijación externa. Se muestra también un listado de referencais bibliográficas que puede facilitar la búsqueda o ampliación de los conocimientos de los profesionales interesados en este tema

Morbimortalidad, clasificación, examen físico y evaluación radiográfica de las fracturas de pelvis / Morbimortality, physical examination and radiographic evaluation of pelvis fracture

Se realizó un estudio biliográfico de actualización acerca del abordaje, manejo y control del paciente afectado de fractura de pelvis. Se analiza la morbimortalidad y sus factores contribuyentes, la anatomía de la pelvis, las principales clasificaciones de esre tipo de lesión y se particulariza en las clasificaciones de Tile y Deenis. Se abordan también por su importancia el examen físico y la evaluación radiográfica. Se concluye la necesidad de adoptar un protocolo institucional para el tratamiento de pacientes politraumatizados con este tipo de fractura(AU)

Morbimortalidad, clasificación, examen físico y evaluación radiográfica de las fracturas de pelvis / Morbimortality, physical examination and radiographic evaluation of pelvis fracture

Se realizó un estudio biliográfico de actualización acerca del abordaje, manejo y control del paciente afectado de fractura de pelvis. Se analiza la morbimortalidad y sus factores contribuyentes, la anatomía de la pelvis, las principales clasificaciones de esre tipo de lesión y se particulariza en las clasificaciones de Tile y Deenis. Se abordan también por su importancia el examen físico y la evaluación radiográfica. Se concluye la necesidad de adoptar un protocolo institucional para el tratamiento de pacientes politraumatizados con este tipo de fractura

Injerto vascularizado de Peroné y minifijador externo en defectos óseos del miembro superior / Vascularized fibular graft and external minifixator in bone defects of the upper extremity

Se realiza un estudio retrospectivo descriptivo donde se muestran los resultados de 10 pacientes tratados con injerto vascularizado de peroné y minifijador externo modelo del Profesor Dr. Sc. Rodrígo Álvarez Cambras, tratados en el período comprendido de enero de 1996 a febrero del 2001, debido a defectos óseos > 6 cm con el objetivo de evaluar la efectividad de esta técnica quirúrgica. De estos pacientes, el 50 (por ciento) pertenece al sexo masculino y femenino respectivamente, con rango de edad entre 12 y 48 años, (el 20 por ciento húmero, 50 por ciento cúbito y 30 por ciento radio). El tiempo promedio de consolidación fue de 29 semanas. De las complicaciones 2 requirieron tratamiento quirúrgico (20 por ciento). Un foco seudoartrósico y una fractura por fatiga que se solucionaron con tratamiento quirúrgico. La evaluación de la técnica fue de 8 (80 por ciento) bueno y 2 (20 por ciento) regular, por lo que podemos concluir que la técnica efectiva para los defectos óseos > 6 cm en el miembro superior(AU)

Injerto vascularizado de Peroné y minifijador externo en defectos óseos del miembro superior / Vascularized fibular graft and external minifixator in bone defects of the upper extremity

Se realiza un estudio retrospectivo descriptivo donde se muestran los resultados de 10 pacientes tratados con injerto vascularizado de peroné y minifijador externo modelo del Profesor Dr. Sc. Rodrígo Álvarez Cambras, tratados en el período comprendido de enero de 1996 a febrero del 2001, debido a defectos óseos > 6 cm con el objetivo de evaluar la efectividad de esta técnica quirúrgica. De estos pacientes, el 50 (por ciento) pertenece al sexo masculino y femenino respectivamente, con rango de edad entre 12 y 48 años, (el 20 por ciento húmero, 50 por ciento cúbito y 30 por ciento radio). El tiempo promedio de consolidación fue de 29 semanas. De las complicaciones 2 requirieron tratamiento quirúrgico (20 por ciento). Un foco seudoartrósico y una fractura por fatiga que se solucionaron con tratamiento quirúrgico. La evaluación de la técnica fue de 8 (80 por ciento) bueno y 2 (20 por ciento) regular, por lo que podemos concluir que la técnica efectiva para los defectos óseos > 6 cm en el miembro superior